Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Expression of Fas ligand in metastatic prostatic carcinoma: Suggestive of possible clonal expansion of subpopulation with metastatic potential
Autore:
Yeh, YA; Wang, JW; Fan, CY; MacLeod, SL; Fan, K;
Indirizzi:
John L McClellan VA Hosp, Dept Pathol, Little Rock, AR 72205 USA John L McClellan VA Hosp Little Rock AR USA 72205 ttle Rock, AR 72205 USA John L McClellan VA Hosp, Dept Surg, Little Rock, AR 72205 USA John L McClellan VA Hosp Little Rock AR USA 72205 ttle Rock, AR 72205 USA Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY USA Columbia Univ New York NY USA Phys & Surg, Dept Pathol, New York, NY USA Univ Massachusetts, Dept Pathol, Worcester, MA 01605 USA Univ Massachusetts Worcester MA USA 01605 Pathol, Worcester, MA 01605 USA Univ Arkansas Med Sci, Little Rock, AR 72205 USA Univ Arkansas Med Sci Little Rock AR USA 72205 Little Rock, AR 72205 USA
Titolo Testata:
DIAGNOSTIC MOLECULAR PATHOLOGY
fascicolo: 4, volume: 10, anno: 2001,
pagine: 236 - 241
SICI:
1052-9551(200112)10:4<236:EOFLIM>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; IMMUNE ESCAPE; DEATH FACTOR; CD95 LIGAND; APOPTOSIS; ADENOCARCINOMA; PRIVILEGE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Fan, K John L McClellan VA Hosp, Dept Pathol & Lab Med, 4300 W 7th St, Little Rock, AR 72205 USA John L McClellan VA Hosp 4300 W 7th St Little Rock AR USA 72205 USA
Citazione:
Y.A. Yeh et al., "Expression of Fas ligand in metastatic prostatic carcinoma: Suggestive of possible clonal expansion of subpopulation with metastatic potential", DIAGN MOL P, 10(4), 2001, pp. 236-241

Abstract

Fas ligand (FasL) is a type II transmembrane tumor necrosis factor family protein, known to trigger apoptosis in cells that bear the FasL receptor, Fas. The authors found that normal prostate, benign hyperplasia, and most prostatic carcinoma cells at the primary site did not express FasL, whereas metastatic prostatic carcinoma cells in lymph nodes and bone marrow displayed almost uniform. immunohistochemically detectable. FasL expression. However, small foci of FasL-positive prostatic carcinoma cells amid a vast majority of FasL-negative tumor cells were noted at the primary sites in patientswith distant metastases. Analysis of the FasL gene and its mRNA by polymerase chain reaction and reverse transcriptase-polymerase chain reaction, respectively, suggested that the expression of immunohistochemically detectable FasL in metastatic tumor cells was not due to mutation in the FasL gene with resulting overexpression. Further. FasL expression was detectable in the acinar epithelial cells of prostates with morphologic atrophic changes, suggesting that FasL also plays a role in the physiologic apoptosis process of noncancerous prostate. The current data suggest that a subpopulation of prostate carcinoma cells clonally expresses FasL, and this subpopulation may have metastatic potential. Evaluation of FasL expression in the primary tumor thus may provide a useful parameter for predicting metastatic potential of the tumor.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 00:26:31